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Objectives This study was designed to compare the outcomes of paclitaxel-eluting stents (PES) and sirolimus-eluting stents
(SES) in a contemporaneous cohort of real-world patients.
Background A number of randomized comparisons of PES and SES have shown unequivocal advantages for SES in angio-
graphic end points such as late loss. However, the data on clinical outcomes are less consistent.
Methods All consecutive patients successfully treated with only SES or PES in de novo native vessel lesions between
March 2003 and March 2005 were analyzed. Our end points were major adverse cardiac events (MACE), a com-
posite of death, myocardial infarction (MI), target vessel revascularization (TVR), and target lesion revasculariza-
tion (TLR). We also analyzed late loss and angiographic restenosis.
Results There were 609 patients (1,064 lesions) treated with PES and 674 patients (1,205 lesions) treated with SES.
Diabetes mellitus was present in 26.8% of patients and multivessel disease in 75% of patients. Bifurcations
made up 16.3% of lesions, chronic occlusions 9.5%, left main 4.8%, and American Heart Association/American
College of Cardiology type B2/C 75.4%. Despite a higher late loss in the PES group (p  0.0001), there were no
differences in angiographic restenosis (PES 18% vs. SES 17.8%, p  0.95), TLR (PES 11.9% vs. SES 11%, p 
0.47), or MACE (PES 21.3% vs. SES 21.1%, p  0.95). The relative risk of MACE for the PES group was 1.02
(95% confidence interval [CI] 0.78 to 1.33). Multivariable analysis confirmed the lack of association of stent type
with MACE (odds ratio 1.03 [95% CI 0.77 to 1.38], p  0.83) and TLR (odds ratio 1.08 [95% CI 0.81 to 1.44],
p  0.61).
Conclusions In this complex cohort, both stent platforms demonstrated similar clinical outcomes despite different late
loss. (J Am Coll Cardiol 2007;49:2320–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.057t
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lince the advent of drug-eluting stents (DES), much
nterest has focused on the comparison of the outcomes
ollowing implantation of the 2 initially available platforms:
ypher (Cordis/Johnson and Johnson, Warren, New Jersey)
nd Taxus (Boston Scientific, Natick, Massachusetts) (1,2).
number of randomized comparative studies have been
erformed; however, only SIRTAX (Sirolimus-Eluting and
aclitaxel-Eluting Stents for Coronary Revascularization)
ad a clinical primary end point which was 9-month major
dverse cardiac events (MACE) (3–9). The data from these
rom the *EMO Centro Cuore Columbus, Milan, Italy; †San Raffaele Scientific
nstitute, Milan, Italy; ‡Abano Terme Hospital, Abano Terme, Italy; and §Antwerp
ardiovascular Institute, AZ Middelheim, Antwerp, Belgium.c
Manuscript received December 5, 2006; revised manuscript received February 2,
007, accepted February 19, 2007.rials are conflicting, with SIRTAX demonstrating signifi-
antly lower target lesion revascularization (TLR) rates for
he sirolimus-eluting stent (SES) compared to the
aclitaxel-eluting stent (PES) and REALITY showing no
ifference. The other studies were underpowered for clinical
nd points, although ISAR-Diabetes (The Intracoronary
tenting and Angiographic Results: Do Diabetic Patients
erive Similar Benefit from Paclitaxel-Eluting and
irolimus-Eluting Stents), ISAR-Desire (Intracoronary
tenting and Angiographic Results: Drug-Eluting Stents
or In-Stent Restenosis), BASKET (Basel Stent Kosten
ffektivitäts Trial), and CORPAL (Cordoba–Las Palmas
tudy) all demonstrated a nonsignificant trend toward a
ower TLR rate for SES.
Despite the lack of clearly demonstrable differences inlinical events, all the studies have shown unequivocal advan-
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June 19, 2007:2320–8 Drug-Eluting Stents in Real-World Lesionsages for SES in late loss. Surrogate end points such as late loss
re attractive for comparing different DES, as a continuous
ariable is more powerful and hence reduces the sample size
equired to demonstrate a significant difference (10).
In light of the apparent paradox between clinical and
urrogate end points in the randomized trials, a contempo-
aneous comparison between PES and SES was performed
rom our practice, which includes complex lesion subsets
nderrepresented in these trials.
ethods
ll consecutive patients treated with either PES or SES
etween March 2003 and March 2005 were considered for
etrospective analysis. The study period was selected as PES
ecame available for clinical use in our institution in March
003. The exclusion criteria were a mixture of different
ypes of DES, a mixture of bare-metal stents and DES,
n-stent restenosis, lesions located in bypass conduits, and
rimary balloon angioplasty.
All patients provided informed consent for both the
rocedure and subsequent data collection and analysis for
esearch purposes. Procedural antiplatelet therapy and hep-
rin dosing followed standard protocols (11). Platelet glyco-
rotein IIb/IIIa receptor inhibitors, an interventional ap-
roach, and intravascular ultrasound usage were used at the
perator’s discretion. Stent selection, although not random-
zed, was performed without any specific preference, and it
s our practice to alternate the implantation of 1 DES with
he other.
linical definitions and follow-up. Clinical follow-up
as performed by telephone contact or office visit at 1, 6,
, and 12 months after the index procedure. Angio-
raphic follow-up was suggested for all patients at 6 to 9
onths after procedure. The clinical end points analyzed
ere periprocedural myocardial infarction (MI), death,
fter-discharge MI, target vessel revascularization (TVR),
nd TLR during the total follow-up period. Major adverse
ardiac events, defined as a composite of death, MI, and
VR, were evaluated on a per patient basis. We analyzed
LR separately on a per lesion basis. All deaths were
onsidered cardiac unless otherwise documented. We de-
ned MI as a total creatine kinase elevation of 2 times the
pper limit of normal in combination with an elevation in
he creatine kinase-MB fraction. We defined TLR as repeat
evascularization secondary to a stenosis 50% within the
tent or within the 5-mm borders proximal or distal to the
tent edge at the follow-up angiogram. We defined TVR as
epeat revascularization of the target vessel.
uantitative coronary angiography analysis. Coronary
ngiograms were analyzed using the validated edge detec-
ion system (CMS, version 5.2, MEDIS, Leiden, the
etherlands) (12). Angiographic restenosis was defined as
iameter stenosis 50% by quantitative coronary angiogra-
hy within a previously stented segment (stent and 5 mm
roximal and distal) at the follow-up angiogram. Acute gain sas defined as the difference be-
ween the minimal lumen diam-
ter (MLD) at baseline and im-
ediately after the procedure.
ate lumen loss was calculated as
he difference in MLD immedi-
tely after procedure and at an-
iographic follow-up.
tatistical analysis. Continuous
ariables are presented as means
SD or medians (interquartile
ange [IQR]) and categorical
ariables as frequencies (%).
he normality of the distribu-
ion of the continuous variables
as tested by the Kolmogorov-
mirnov goodness-of-fit test. A
kewness index was used to assess
he nature of the asymmetry of
he distribution. A normal distri-
ution has a skewness value of
ero, as it is symmetric. A distri-
ution with a significant positive
kewness is right-skewed and has
long right tail, whereas a neg-
tively skewed distribution has a long left tail. Continuous
ariables were compared using independent sample Student
or Mann-Whitney U test. Categorical variables were
ompared with chi-square statistic or Fisher exact test where
ppropriate. The Fisher exact test was used when the
arametric assumptions underlying chi-square did not hold
conventionally, when the number of events in one or more
lasses is 5). The Mann-Whitney U test was used when
he parametric assumptions underlying the Student t test
id not hold. All the categorical variables were compared
ith the chi-square test, apart from acute thrombosis,
ubacute thrombosis, and coronary bypass surgery. All
ontinuous variables were compared using the Student t
est, apart from the length of clinical follow-up and some of
he quantitative angiographic parameters.
We calculated 95% confidence intervals (CI) for propor-
ions by the Wilson method and the relative risk by the
xact method (13,14).
Exploratory multivariable analysis was performed to as-
ess the impact of stent type on the risk of MACE and TLR
y logistic regression. The final model included variables
ssociated at univariate analysis with MACE and TLR (all
ith a p value 0.1). The results are reported as adjusted
dds ratios (OR) with associated 95% CI. To account for
otential differences between the SES and PES cohorts, a
ropensity analysis was performed on a lesion-based setting
or TLR using the propensity score as a covariate in the
ogistic regression model (15,16).
A p value of 0.05 was considered to be statistically
Abbreviations
and Acronyms
AHA/ACC  American
Heart Association/
American College of
Cardiology
CI  confidence interval
DES  drug-eluting stent(s)
IQR  interquartile range
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimal lumen
diameter
OR  odds ratio
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationignificant, and all reported p-values are 2-sided. Statistical
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Drug-Eluting Stents in Real-World Lesions June 19, 2007:2320–8nalysis was performed using SPSS version 11.5 (SPSS Inc.,
hicago, Illinois) and Confidence Interval Analysis (13).
esults
uring the study period, a total of 1,907 patients were treated
ith a DES: 338 were treated for restenotic lesions, 232 had a
ixture of different types of stent implanted, and 54 patients
ere treated for lesions located in bypass conduits.
The remaining 1,283 patients constituted the study
ohort: 609 (1,064 lesions) received a PES and 674 (1,205
esions) received a SES. Baseline demographic and proce-
ural data are presented in Tables 1 and 2. Overall, this was
complex cohort of patients, with a high percentage of
ulti-vessel disease (75%), prior bypass surgery (18%), and
iabetes mellitus (27%). Lesion complexity was also note-
orthy: there were chronic total occlusions (9.5%), bifurca-
ions (16%), and a high percentage of American Heart
ssociation/American College of Cardiology (AHA/ACC)
ype B2/C lesions (74%). This complexity was also repre-
ented by the number of stents implanted (range 1 to 10)
nd the total stent length per patient (range 8 to 255 mm).
he patient characteristics were similar in the 2 groups,
part from a higher incidence of prior bypass surgery (p 
.009) and insulin-requiring diabetes mellitus (p  0.007)
n the PES cohort. In the PES group, there were more
HA/ACC type B2/C lesions (p  0.002), and there was
Baseline Clinical and ProceduralCharacteristics of the Pati nts Treated in the 2
Table 1 Baseline Clinical and ProceduralCharacteristics of the Patients Trea
Variable PES
Patients n  60
Age, yrs 62.96 1
Age75 yrs 13.6% (8
Ejection fraction (%) 52.96 9
Male gender 86.9% (5
Prior myocardial infarction 51.1% (3
Prior coronary angioplasty 38.4% (2
Prior coronary bypass surgery 21.5% (1
Risk factors
Family history 43.2% (2
Hypertension 68.1% (4
Hypercholesterolemia 70.6% (4
Current smoker 16.1% (9
Diabetes mellitus 28.1% (1
Diet-controlled 3.9% (2
Oral hypoglycemics 14.6% (8
Insulin 9.5% (5
Unstable angina pectoris 26.3% (1
Multivessel disease 75.7% (4
Intra-aortic balloon pump 3.3% (2
Glycoprotein IIb/IIIa inhibitor 10% (6
Number of stents per patient 1.98 1
Range 1–9
Total stent length, mm 48.69 3
Range 8–232Data are presented as percentages or means  SD, unless otherwise specifi
PES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.higher use of both cutting balloon (p  0.002) and
ntravascular ultrasound (p  0.0001).
Clinical follow-up was available in 99.1% of patients at a
edian of 13.9 months (IQR 11.5 to 17.5) after the
rocedure. Only 12 patients were lost to follow-up (4 in the
ES group and 8 in the SES group). There was no
ifference in the length of follow-up between the 2 groups:
3.6 months (IQR 11.3 to 16.9) and 13.8 months (IQR
1.6 to 17.5) (p  0.35) for PES and SES, respectively.
The MACE rate was 21.3% (95% CI 18.3% to 24.8%) in
he PES group and 21.1% (95% CI 18.2% to 24.3%) in the
ES group (p  0.95), and there were no differences between
he groups in the rate of follow-up death, MI, or late stent
hrombosis (Table 3). The relative risk of MACE for the PES
roup compared to the SES was 1.02 (95 % CI 0.78 to 1.33).
multivariable model that included age, ejection fraction,
ulti-vessel disease, previous bypass surgery, intra-aortic bal-
oon pump use, glycoprotein IIb/IIIa inhibitor administration,
nd diabetes mellitus showed that the type of stent implanted
as not associated with MACE (OR 1.04 [95% CI 0.78 to
.38], p 0.8). Multi-vessel disease (OR 1.66 [95% CI 1.13 to
.5], p 0.01), intra-aortic balloon pump use (OR 3.19 [95% CI
.6 to 6.33], p 0.001), and diabetes mellitus (OR 2.42 [95% CI
.79 to 3.27], p  0.0001) were all associated with MACE.
A lesion-based analysis revealed that there was an 11.9%
95% CI 10.1% to 14%) TLR rate in PES compared with
ps
n the 2 Groups
SES p Value
n  674
62.92 10.7 0.95
14.2% (96) 0.81
52.75 10.1 0.71
86.1% (580) 0.68
48.1% (324) 0.29
37.7% (254) 0.82
15.7% (106) 0.009
44.4% (299) 0.69
65.1% (439) 0.26
67.4% (454) 0.23
15.1% (102) 0.65
25.4% (171) 0.28
3.0% (20) 0.36
16.9% (114) 0.28
5.5% (37) 0.007
28.3% (191) 0.42
74.4% (501) 0.61
3.1% (21) 0.88
14.7% (99) 0.014
2.02 1.4 0.52
1–10
51.48 38 0.17
8–255Grou
ted i
9
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.86
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34)
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June 19, 2007:2320–8 Drug-Eluting Stents in Real-World Lesions1.0% (95% CI 9.3% to 12.8%) in the SES group (p  0.47)
nd a TVR rate of 16.4% (95% CI 14.2% to 18.8%) compared
ith 15.1% (95% CI 13.2% to 17.2%) respectively (p  0.39)
Table 3). The variables entered into the multivariable model
or TLR were reference vessel diameter, postprocedural MLD,
tent length, stent diameter, number of stents per lesion, and
iabetes mellitus. This showed that stent type was not associ-
ted with TLR (OR 1.1 [95% CI 0.84 to 1.48], p 0.47). The
Baseline and Procedural Characteristics of the L
Table 2 Baseline and Procedural Characteri
Variable PES
Lesions n 1,064
Vessel involved
Left main stem 5.3% (82
Left anterior descending 36.7% (39
Circumflex 16.8% (17
Right coronary artery 19.5% (20
Bifurcations 15.8% (16
Chronic total occlusions 10.1% (10
Calcified lesions 22.5% (23
AHA/ACC B2/C lesion type 78.3% (81
Directional atherectomy 1.3% (14
Rotational atherectomy 2% (21
Cutting balloon 4.8% (51
Intravascular ultrasound 14.9% (15
Number of stents per lesion 1.13 0.
Stent length, mm 27.9 13
Stent diameter, mm 3.0 0.
Max. balloon diameter, mm 3.03 0.
Max. inflation pressure, atm 15.44 3.
Data are presented as percentages or means  SD.
AHA/ACC  American Heart Association/American College of Card
In-Hospital, 30-Day, and Follow-Up Clinical Even
Table 3 In-Hospital, 30-Day, and Follow-Up C
Variable
Patients n
Periprocedural myocardial infarction 3.9
Acute thrombosis
Follow-up (except periprocedural MI)
Total death 2.6
Cardiac 1.8
Myocardial infarction 2.8
Subacute thrombosis 0.7
Late thrombosis 1.3
TLR (per-patient) 14.8
TVR (per-patient) 18.2
MACE 21.3
Coronary bypass surgery 1.1
Multiple MACE 2.1
Angiographic follow-up 72.5
Lesions n 
TLR (per-lesion) 11.9
TVR (per-lesion) 16.4
Angiographic follow-up 73.6
Data are presented as percentages and absolute numbers.
MACE  major adverse cardiac events; TLR  target-lesion revascularizat
Table 1.umber of stents per lesion (OR 1.95 [95% CI 1.16 to 3.29],
 0.012) and diabetes mellitus (OR 1.63 [95% CI 1.22 to
.19], p  0.001) were associated with TLR. A propensity
nalysis confirmed the lack of association between TLR
nd the type of stent implanted (OR 1.05 [95% CI 0.81
o 1.37], p  0.7).
uantitative angiographic analysis. Serial quantitative
oronary angiography data are shown in Table 4. Angio-
ns Treated in the 2 Groups
of the Lesions Treated in the 2 Groups
SES p Value
n 1,205
4.2% (51)
36.3% (438)
14.8% (178)
21.5% (259)
16.8% (203) 0.53
9% (108) 0.39
19.9% (240) 0.15
72.5% (859) 0.002
0.5% (6) 0.043
1.1% (13) 0.09
2.4% (29) 0.003
8.5% (102) 0.0001
1.13 0.4 0.9
28.8 13.3 0.14
2.97 0.39 0.03
3.02 0.42 0.39
15.49 3.4 0.75
other abbreviations as in Table 1.
the 2 Groups
al Events in the 2 Groups
SES p Value
n 674
1.8% (12) 0.03
0.3% (2) 0.5
2.7% (18) 1.0
2.4% (16) 0.56
1.5% (10) 0.12
0.1% (1) 0.2
0.7% (5) 0.41
15.7% (106) 0.64
) 18.7% (126) 0.89
) 21.1% (142) 0.95
0.4% (3) 0.21
1.5% (10) 0.41
) 67.7% (448) 0.07
n  1,205
) 11% (132) 0.47
) 15.1% (182) 0.39
) 70.3% (829) 0.09esio
stics
)
0)
9)
8)
8)
7)
9)
9)
)
)
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9)
42
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Drug-Eluting Stents in Real-World Lesions June 19, 2007:2320–8raphic follow-up was available in 766 lesions in the PES
roup (73.6%) and 829 lesions (70.3%) in the SES group.
here was no statistical difference in restenosis rates be-
ween the PES and SES groups (18% [95% CI 15.5% to
0.9%] compared with 17.8% [95% CI 15.4% to 20.6%],
 0.95). The late lumen loss was not normally distributed
or both stents (p  0.0001 by the Kolmogorov-Smirnov
oodness-of-fit test) and was positively skewed with a long
ight tail (skewness index PES 0.89, SES 0.98). It was
igher in the PES group: 0.45 mm (IQR 0.07 to 0.99)
ompared with 0.23 mm (IQR 0.02 to 0.69) in the SES
roup (p  0.0001) (Fig. 1A). To further investigate this
isparity between late loss and angiographic restenosis,
e divided the late loss according to the presence of
ngiographic restenosis. Following this division, the distri-
ution of late loss was normal for both stents (nonrestenotic
esions PES p 0.54, SES p 0.55, restenotic lesions PES
 0.96, SES p  0.48, by the Kolmogorov-Smirnov
oodness-of-fit test) (Figs. 1B and 1C). The late loss of the
onrestenotic lesions was significantly higher in the PES
roup: 0.32  0.55 mm compared with 0.06  0.52 mm in
he SES group (p  0.0001). In the restenotic lesions, there
as no difference in late loss between the 2 groups: PES
Quantitative Coronary Angiographic Data
Table 4 Quantitative Coronary Angiographic
Variable
Before procedure
Lesions n
Reference vessel diameter, mm 2.65
Minimal luminal diameter, mm*
IQR (0.5
Diameter stenosis, %* 6
IQR (5
Lesion length, mm* 1
IQR (7
After procedure
Reference vessel diameter, mm 3.16
Minimal luminal diameter, mm 2.8
Diameter stenosis, %* 1
IQR (5
Acute gain, mm*
IQR (1
Follow-up
Lesions n
Reference vessel diameter, mm 2.98
Minimal luminal diameter, mm*
IQR (1
Diameter stenosis, %* 1
IQR (9
Late lumen loss, mm 0.52
Late lumen loss, mm median*
IQR (0.0
Angiographic restenosis 18
Focal pattern 53.6
Data are presented as means  SD or percentages unless otherwise
IQR  interquartile range; other abbreviations as in Table 1..78  0.72 mm compared with SES 1.7  0.69 mm Ip  0.39). When the curves of the nonrestenotic and
estenotic lesions were superimposed, there was an area of
artial overlap for late loss values between 0.5 and 1.5 mm
pproximately (Figs. 2A and 2B).
iscussion
he main findings of this report are: 1) MACE and TLR
ates in this complex cohort of patients were higher than
hose seen in the randomized trials; 2) there was no
ifference in the incidence of clinical end points between
ES and SES; and 3) late loss was significantly greater
ollowing PES implantation, but this did not translate into
higher restenosis or TLR rate.
The MACE and TLR rates in this cohort were higher
han those seen in the randomized trials. However, the
andomized trials enrolled a select group of patients and
esions (1,2). The most complex cohort to date was enrolled
n the TAXUS-V trial; this demonstrated a MACE rate of
5% and a TLR rate of 8.6% in the PES arm (17). This trial
ncluded only single-vessel intervention. Left main, aorto-
stial lesions, chronic total occlusions, bifurcations, calcified
esions, and the planned use of atherectomy were excluded.
SES p Value
n 1,205
2 2.67 0.65 0.55
0.87 0.81
) (0.58–1.2)
65 0.78
(55–76)
11.8 0.57
8) (7.7–18.4)
3 3.1 0.55 0.009
3 2.72 0.53 0.0001
11.4 0.015
(6.2–17.6)
1.78 0.001
) (1.4–2.2)
n 829
5 3.1 0.58 0.0001
2.5 0.002
) (1.9–3)
16 0.12
(8.3–31)
6 0.27 0.75 0.0001
0.23 0.0001
9) (0.2–0.69)
8) 17.8% (148) 0.95
) 72.3% (107) 0.001
d. *Median data are presented.Data
PES
1,064
 0.6
0.87
6–1.2
6
5–77)
1.8
.6–17.
 0.5
 0.5
0.8
.4–16)
1.87
.5–2.3
 766
 0.5
2.4
.8–2.8
6.8
.6–32)
 0.7
0.45
7–0.9
% (13
% (74n contrast, our population comprised a spectrum of de novo
2325JACC Vol. 49, No. 24, 2007 Cosgrave et al.
June 19, 2007:2320–8 Drug-Eluting Stents in Real-World LesionsFigure 1 Distribution of Late Loss of Both SES and PES
(A) Distribution of late loss of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for the total cohort. Late loss was not normally distributed (p  0.0001)
and was higher in the PES group: 0.45 mm (interquartile ratio [IQR] 0.07 to 0.99) compared with 0.23 mm (IQR 0.02 to 0.69) after SES, p  0.0001. (B) Distribution
of late loss of both SES and PES for nonrestenotic lesions. Late loss was normally distributed and was significantly higher in the PES group: 0.32  0.55 mm compared
with 0.06  0.52 mm, p  0.0001. (C) Distribution of late loss of both SES and PES for restenotic lesions. Late loss was normally distributed, and there was no differ-
ence in late loss between the 2 groups: PES 1.78  0.72 mm compared with SES 1.7  0.69 mm, p  0.39.
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Drug-Eluting Stents in Real-World Lesions June 19, 2007:2320–8ative coronary lesions and was substantially more complex
han those of the randomized trials. Multi-vessel disease,
hronic total occlusions, left main, bifurcations, and diffuse
isease that required long stent lengths were included.
herefore, the MACE and TLR rates are a more accurate
epresentation of the efficacy of these stents in complex
atients and lesions. Although the restenosis rates were
igh, the majority demonstrated a focal pattern and were
menable to repeat percutaneous therapy (18,19).
The performance of PES and SES was similar for
ACE and TLR. This similarity was confirmed by multi-
ariable analysis. The relatively high event rate in our
opulation and the narrow CI make this observation more
eliable. The relative risk of MACE for the PES cohort
pproaches unity (1.02 [95% CI 0.78 to 1.33]). The 2
roups were similar, but there were some differences that
ould have favored the SES group. The incidence of
nsulin-requiring diabetes, prior bypass surgery, AHA/
CC type B2/C lesions, and atheroablation were all higher
n the PES cohort. Despite these differences, the outcomes
ere similar. To account for these baseline differences, a
ropensity analysis was performed on a lesion basis for
LR. This again confirmed the lack of association of stent
ype with revascularization. There was a numerically higher
ncidence of ST in patients treated with PES; however, this
ifference was not statistically significant and, because of the
nfrequent occurrence of ST, a specific large trial would be
equired to clarify this issue.
An apparent contradiction from our data is that late loss
as significantly higher in the PES group, yet restenosis and
LR rates were similar between the 2 stents. This paradox
an be explained in 2 ways. First, late loss is a calculated
verage of non-normally distributed data, and many patients
Figure 2 Distribution of Late Loss of Both SES and PES for the
Demonstrating the Area of Overlap for the Nonresteno
Abbreviations as in Figure 1.ave luminal loss that does not cause angiographic resteno- sis (20). A patient may have 1.5 mm of late loss in a 3.5-mm
tent and hence not have restenosis, whereas another with
he same degree of late loss but in a 2.5-mm stent would be
haracterized as restenosis. Indeed, in our data there is a
artial overlap between the curves for restenotic and non-
estenotic lesions (Fig. 2). Thus, the correlation between the
egree of late loss and restenosis is not a linear one; complex
ata transformations have been proposed to overcome this
roblem but with limited success (21,22). Another expla-
ation may be that SES demonstrates an all-or-nothing
esponse; in patients who do not develop restenosis, the late
oss may be extremely low and approaches zero (23). In
ontrast, following PES implantation there is some degree
f neointimal hyperplasia, as evidenced by the amount of
ate loss in the TAXUS-IV study (2). Although the
AXUS-IV and SIRIUS studies are not directly compara-
le, the degree of late loss is greater in TAXUS-IV (0.39 
.5 mm compared with 0.17  0.45 mm in SIRIUS).
espite this, the TLR rates were similar (3% and 4.1%,
espectively). In the present study, the late loss in the
onrestenotic lesions was significantly higher following PES
mplantation (0.32 0.55 mm compared with 0.06 0.52,
 0.0001). In contrast, for lesions with angiographic
estenosis, the late loss was similar (PES 1.78  0.72 mm,
ompared with SES 1.7 0.69, p 0.39).The difference in
ate loss between the 2 groups in our cohort was due
rimarily to the difference observed in nonrestenotic lesions.
hus, although SES seems to approach an all-or-none
esponse, PES still exhibits some degree of neointimal
yperplasia (24). This difference in mild intimal hyperplasia
s unlikely to affect clinical outcomes and explains the
pparent paradox between higher late loss in PES and
l Cohort,
nd Restenotic LesionsTota
tic aimilar TLR rates.
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June 19, 2007:2320–8 Drug-Eluting Stents in Real-World LesionsAlthough our MACE and TLR rates are higher than
hose seen in the REALITY trial, the discordance between
ate loss and restenosis and TLR point in the same direc-
ion. This study enrolled 1,386 patients with 1 or 2 de novo
esions; however, left main, calcified lesions, total occlu-
ions, acute MI, and pretreatment other than balloon
ngioplasty were all excluded (3). All patients were sched-
led for angiography at 8 months, and the primary end
oint was binary angiographic restenosis. The study consid-
red TLR, TVR, MACE, and late loss secondary end
oints. Angiographic follow-up was available in 88% of the
ES patients and 93% of the SES patients. Mean late loss
as significantly higher following PES (0.31 0.44 mm vs.
.09 0.43 mm following SES, p 0.001). However, both
he restenosis (11.1% for PES and 9.6% for SES, p  0.31)
nd TLR rates (6.1% and 6% respectively, p  0.99) were
imilar.
The SIRTAX trial enrolled 1,012 patients with 1,401
esions (4). Although this study enrolled consecutive real-
orld patients and included acute coronary syndromes
51.4%), chronic occlusions (1.8%), bifurcations (8.4%), left
ain (1.6%), and calcified lesions (34.5%), the overall
ercentage of AHA/ACC type B2/C lesions was still quite
ow at 36.4%. Therefore, the population is not directly
omparable to ours in terms of patient and lesion complex-
ty. The incidence of the primary end point of MACE at 9
onths was significantly greater in the PES group (10.8%
s. 6.2%, p  0.009), a fact that was driven primarily by
ifferences in revascularization rates. Overall angiographic
ollow-up was available in 540 (53.4%) patients with 723
esions. The in-stent late loss was again greater following
ES implantation (0.25 0.49 mm) compared with 0.12
.36 mm (p  0.001), and there was a corresponding
ncrease in in-stent and in-segment binary angiographic
estenosis (in-stent 7.5% compared with 3.2%, p 0.01 and
n-segment 11.7% compared with 6.6%, p  0.02, respec-
ively). We must be cautious in drawing too many conclu-
ions from this angiographic data in light of the low rate of
ngiographic follow-up.
A meta-analysis of the randomized comparative data has
een published by Kastrati et al. (25). This analysis included
ata from REALITY, SIRTAX, CORPAL, TAXI, ISAR-
ESIRE, and ISAR-DIABETES. The TLR rate for SES
as 5.1% compared with PES at 7.8%, which gave a pooled
R of 0.64 (95% CI 0.49 to 0.84, p 0.001).The restenosis
ate was also lower for SES (9.3% compared with 13.1%,
R of 0.68, 95% CI 0.55 to 0.86, p  0.001). Although
hese data are interesting, only 1 of the included trials had
clinical primary end point. It does not necessarily follow
hat grouping together such studies will generate sufficient
ower to result in a low likelihood of any differences identified
n clinical end points remaining susceptible to a type 2 error
26).
tudy limitations. The most important limitation is the
ack of randomization. Despite this, the 2 groups were well
atched, and our results were confirmed by both multiva-
1iable and propensity analysis. The relatively low rate of
ngiographic follow-up must also be considered a limita-
ion, which may artificially elevate the rate of restenosis;
owever, the angiographic follow-up was similar in the 2
roups. Moreover, clinical follow-up was available in 99.1%
f patients at a median of 13.9 months, and our primary
oal was to comment on the clinical outcomes of the 2 study
tents. We must also acknowledge that our sample size is
elatively small to detect small differences in the event rates
etween the 2 stents.
onclusions
espite significant difference in the surrogate end point of
ate loss, PES and SES demonstrated similar clinical out-
omes in this complex cohort. This suggests that late loss
ay not be a suitable end point for the evaluation of the
erformance of these 2 stents, especially in this real-world
opulation.
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